Atlas Trials

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

Clinical trial NCT07282197 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07282197
Sponsor
Peking University First Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate Cancer
Start date
2026-01-01
Primary completion
2029-03-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.